// App-Quantinova.ai

: MORE OR LESS? IMPACT OF DOSE NUMBER ON OUTCOMES OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN

Researchers

Presenter

  • David I Marks

Principal Investigators

  • Daniel J DeAngelo

  • Elias Jabbour

  • Anjali Advani

  • Susan OBrien

  • Tao Wang

  • Alexander Neuhof

  • Erik Vandendries

  • Hagop Kantarjian

  • Wendy Stock

  • Matthias Stelljes

  • Ryan Cassaday

Medical Centers

  • University of Bristol, Bristol, United Kingdom

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • University of California, Davis, Davis, California, United States

  • Pfizer Groton CT United States

  • Pfizer Pharma GmbH, Berlin, Germany

  • Pfizer Inc,Cambridge,United States

  • Universitatsklinikum Munster, Munster, Germany

  • University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA

Locations

  • United Kingdom

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Inotuzumab ozogamicin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01564784

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved